Skip to the main content.
Facebook Linkedin X

Copy of Analytical Control MoM

Reduce Risk in Drug Development  

Learn how a strong analytical control strategy reduces risk, prevents costly late-stage failures, and keeps your biologics program on track. Practical insights from Brent Kendrick, PhD, a 30-year biologics development veteran and former VP of R&D at KBI Biopharma. 

Get the Full Video and Guide

Why Analytical Control Strategies Matter  

Analytical control strategy is the framework that connects your science to a successful regulatory submission. Without it, development teams face the same costly, preventable failures that Brent has seen derail programs across his 30-year career.  

Regulatory Risks

Incomplete data or interpretation putting your entire program
at risk

Patient
Safety

Platform methods silently missing aggregates or critical impurities

Costly Lot Rejections

 Out-of-Spec results and failed batches costing millions 

Costly Remediation

Late-stage surprises resulting in repeat studies, stalled timelines, and
rising costs 

What You’ll Learn: 

  • What a strong analytical control strategy actually requires
  • Three reasons a strong strategy prevents failures and reduces risks
  • Two real-world case studies with hard lessons 

Access Both Formats Today! 

Fill out the form above to get instant access to both the full video interview and the comprehensive written guide featuring Dr. Brent Kendrick, founder of First Principles Biopharma and
former VP of R&D at KBI Biopharma.  

Full Video Interview

40-minute comprehensive conversation 
  • Complete interview with
    Brent Kendrick, PhD
  • Real-world case studies and examples
  • In-depth discussion of ICH guidelines and risk assessment strategies

Interactive Guide 

Comprehensive guide with video clips 
  • Comprehensive written resource
  • Key video clips embedded throughout
  • Easy to reference and share

GET THE VIDEO AND GUIDE

Brent Kendrick Headshot

 

MEET YOUR EXPERT: Brent Kendrick, PhD

Consultant & Owner, First Principles Biopharma

Former Vice President of Research and Development, KBI Biopharma

Brent has over 30 years of experience in biologics drug development. After 18 years at Amgen, he co-founded Elion, a contract analytical and formulation laboratory, and served as CSO. Following KBI Biopharma's acquisition of Elion, he served as VP of R&D at KBI until 2021, when he founded First Principles Biopharma, specializing in data analysis, automation, product formulation, analytical development, and product characterization.  


LinkedIn Icon

Want to connect with Brent directly?

Email: brent.kendrick@fp-biopharma.com
Website: fp-biopharma.com

Flexible, Knowledgeable, and Proven


About KBI Biopharma

KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of our 1400+ customer partners, we work closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, we deliver robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial. Recognized for quality manufacturing, we help clients advance drug candidates into the clinic and beyond. 

Science Driven. Customer Focused.